B7-33 6mg

B7-33 6 mg is a synthetic peptide fragment based on a specific segment of the human H2-relaxin protein, engineered to selectively activate the relaxin family peptide receptor 1 (RXFP1) with a bias toward beneficial signalling pathways. Unlike full-length relaxin, which engages multiple intracellular cascades, B7-33 preferentially stimulates the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway and increases the expression of matrix metalloproteinase-2 (MMP-2), an enzyme involved in breaking down excess collagen in the extracellular matrix. This mechanism has made B7-33 of interest in laboratory and preclinical research focused on fibrosis, tissue remodelling, and cardiovascular effects, such as reducing scarring after myocardial injury or attenuating fibrotic encapsulation around implants in animal models.

Despite promising outcomes in experimental systems, B7-33 remains a research compound and is sold strictly for laboratory use, not approved by major regulatory bodies like the U.S. Food and Drug Administration for human therapeutic use. Evidence in humans is minimal, and most available data come from in-vitro or animal studies investigating its effects on fibrosis, extracellular matrix regulation, and cardiovascular signalling. As a result, B7-33 should not be considered a medical treatment, and any exploration of its biological properties should be confined to qualified research settings with proper oversight.